Andy Watson, Anthony Scarpello
Empire Genomics has appointed Andy Watson as CEO and Anthony Scarpello as chief commercialization officer. Watson was previously CEO at Genturi, a genomics technology startup. He was also chief commercial officer at RainDance Technologies, which was acquired by Bio-Rad Laboratories. Prior to Raindance, he was the vice president of SOLiD sequencing product management at Life Technologies, now part of Thermo Fisher Scientific. He also previously led the capillary electrophoresis sequencing business for Applied Biosystems, which became part of Life Technologies.
Scarpello was promoted from vice president of sales and business development to CCO. He joined Empire Genomics in 2009, and previously held numerous senior management roles with Enzo Life Sciences.